Runkai Hu

Runkai Hu

Auto-generated profile, based on publicly available information

Runkai Hu

Department of Pharmacy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2021 in Stem Cells International
Verified
Journal Article
Open access
PDF file
BXBaocheng Xie
Baocheng Xie
SCShichun Chen
Shichun Chen
YXYongxiang Xu
Yongxiang Xu
WHWeichao Han
Weichao Han
RHRunkai Hu
Runkai Hu
SDShao-bo Ding
Shao-bo Ding
Degenerative disc disease (DDD) can cause severe low back pain, which will have a serious negative impact on the ability to perform daily tasks or activities. For the past few years, mesenchymal stem cell (MSC) transplantation has emerged as a promising strategy for the treatment of DDD. However, the clinical efficacy of MSC in the treatment of DDD still lacks clinical evidence and is controversial. We conducted a meta-analysis with randomized controlled trials (RCTs) to evaluate the clinical efficacy and safety of MSC transplantation in patients with DDD. We searched major databases using terms from the database’s inception through March 2021. The Cochrane bias risk assessment tool was used to assess quality. The analysis showed that MSC therapy could decrease visual analog scale (VAS) scores ( , , ) and Oswestry Disability Index (ODI) scores ( , , ). The outcomes with subgroup analysis showed that MSC therapy could decrease VAS scores in 3 months ( ), 6 months ( ), 12 months ( ), and ≥24 months ( ) and ODI scores in ≥24 months ( ). Pooled analysis showed that MSC therapy has a higher ratio of patients at most thresholds but particularly at the MIC (minimally important change) (